Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Compound failures have been emerging in later stages of pharmaceutical drug development and are in many cases not detected until the administration to humans in clinical trials or even after approval. Among the most frequent adverse effects are drug-induced liver injury generated by species-specific susceptibilities (e.g., in xenobiotic metabolism and/or the occurrence of idiosyncratic drug hepatotoxicity). OBJECTIVES: Detecting or predicting unfavorable drug effects on the liver as early as possible in drug development is crucial in making the drug development process more efficient and the application of new drugs to humans in clinical studies and medical use safer. METHODS: To achieve this goal, primary hepatocyte cultures from various species, including humans, are analyzed for morphological, functional and gene expression alterations after compound treatment. RESULTS/CONCLUSION: Primary hepatocyte cultures appear to be a promising tool for the detection of general or liver toxicity and the evaluation of species-specific drug effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 5×
“The drug development process is an extremely challenging field and the predictivity of current safety assessment has not been improved over the last decades [3-5] .”
BackgroundInfluentialLee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Hewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
Self-citationO’Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., et al. (2006) · Archives of Toxicology · doi:10.1007/s00204-006-0091-3 · Cited by 609
Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity
Boelsterli, U. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(03)00368-5 · Cited by 403
Daly, A. K., Aithal, G. P., Leathart, J. B. S., Swainsbury, R. A., Dang, T. S., & Day, C. P. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.023 · Cited by 348 · cited 1×
“In humans either the parent drug or the hydroxylated metabolite is detoxified by conjugation through UGT2B7 and subsequent excretion into the bile ( Figure 1 ) [23] .”
BackgroundUse of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport
Bi, Y.-A., Kazolias, D., & Duignan, D. B. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.009118 · Cited by 216 · cited 1×
“These canalicular structures are functionally active in transporting a fluorescein dye into the extracellular space, resembling ‘canaliculi’ ( [63] and own data, manuscript in preparation).”
Background
Cited by
Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells
Song, Z., Cai, J., Liu, Y., Zhao, D., Yong, J., Duo, S., Song, X., Guo, Y., Zhao, Y., Qin, H., et al. (2009) · Cell Research · doi:10.1038/cr.2009.107 · Cited by 499
3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies
Gunness, P., Mueller, D., Shevchenko, V., Heinzle, E., Ingelman-Sundberg, M., & Noor, F. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft021 · Cited by 236
Competency of different cell models to predict human hepatotoxic drugs
Gómez-Lechón, M. J., Tolosa, L., Conde, I., & Donato, M. T. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.967680 · Cited by 199
“2D Cultures of hepatocytes Monolayer cultures High liver-specific activity (after isolation) Expression of CYP and Phase II enzymes Short-time inducibility of CYP enzymes by xenobiotics Model of choice (human hepatocytes) for drug screening: metabolic profiling, drugdrug interaction, hepatotoxicity Good transferabilit…”
BackgroundDrug‐Induced Hepatotoxicity: Advances in Preclinical Predictive Strategies and Tools
Dambach, D. M. (2014) · Predictive ADMET · doi:10.1002/9781118783344.ch19 · Cited by 4
Metadata
- Authors
- Tuschl, G., Lauer, B., & Mueller, S. O.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa Healthcare
- Published
- 2008-07
- Volume
- 4
- Issue
- 7
- Pages
- 855-870
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2152530502
- Cited by
- 62
- References
- 10
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism. https://app.cochat.ai/papers/10.1517/17425255.4.7.855
- The paper
- Tuschl, G., Lauer, B., & Mueller, S. O. (2008). Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.4.7.855
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.